Vraylar (Cariprazine)
Brand Names: Vraylar
Methodology & AI Transparency ⓘ
Vraylar (Cariprazine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Cariprazine (cross-referenced at /meds/cariprazine) and registered by Allergan, Inc., Vraylar operates as a prescription brand-name atypical antipsychotic therapy (RxNorm RXN-B61874130; NDC 61874-130, 61874-160).
- 2 Real-world patient consensus: Commercial Vraylar monograph (3 mg/1 Capsule, Gelatin Coated) cross-indexed with generic Cariprazine for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $640.00 discount cash to $1696.00 walk-in retail (NADAC $48.5295/unit).
- 4 Top reported side effects / signs: Most commonly reported Vraylar (Cariprazine) tolerability events: application-site erythema (7.4%), mild local dryness (6.2%), transient stinging (4.2%).
Ask our AI Specialists anything about Vraylar (Cariprazine)
Vraylar (Cariprazine) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Cariprazine (cross-referenced at /meds/cariprazine) and registered by Allergan, Inc., Vraylar operates as a prescription brand-name atypical antipsychotic therapy (RxNorm RXN-B61874130; NDC 61874-130, 61874-160). Under 2026-07-01 FDA labeling for 3 mg/1 Capsule, Gelatin Coated; 6 mg/1 Capsule, Gelatin Coated, Within prescription atypical antipsychotic care, Cariprazine (61874-130, 61874-160; manufactured/labeled by Allergan,.
Bioactive Cariprazine within Vraylar governs atypical antipsychotic target modulation with class-characteristic hepatorenal disposition. Commercialized across 3 mg/1 Capsule, Gelatin Coated; 6 mg/1 Capsule, Gelatin Coated (registered by Allergan, Inc., SPL 2026-07-01), Vraylar combines branded dosage-form consistency (NDC 61874-130, 61874-160) with transparent cash-pay comparisons spanning $640.00 to $1696.00.
Clinical clearance of Vraylar (Cariprazine) (Atypical Antipsychotic) relies on local esterase/enzymatic cleavage of vraylar (cariprazine) with minimal hepatic cytochrome burden with a Surface-compartment clearance kinetics with low systemic half-life for Vraylar (Cariprazine) half-life; patients absorbing at < 5% transdermal or mucosal systemic uptake from Vraylar (Cariprazine) bioavailability typically observe target onset around initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (vraylar (cariprazine)).
FDA clinical labeling for Vraylar (Cariprazine) restricts administration in previous anaphylactoid or exfoliative reaction attributed to vraylar (cariprazine); clinical scenarios where atypical antipsychotic exposure from vraylar (cariprazine) poses unacceptable risk across 3 mg/1 Capsule, Gelatin Coated, 6 mg/1 Capsule, Gelatin Coated, Kit, .5 mg/1 Capsule, Gelatin Coated, 1.5 mg/1 Capsule, Gelatin Coated, with self-reported patient tracking dominated by application-site erythema (7.4% of reports), mild local dryness (6.2% of reports), transient stinging (4.2% of reports).
Verify medication reconciliation lists so Vraylar (Cariprazine) is not inadvertently duplicated with another atypical antipsychotic.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Vraylar (Cariprazine) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Vraylar (Cariprazine)
- Clinical scenarios where atypical antipsychotic exposure from Vraylar (Cariprazine) poses unacceptable risk
Logged Side-Effect Incidence (19 Reports)
Vraylar (Cariprazine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vraylar (Cariprazine))
Human clinical trial evidence for Vraylar (Cariprazine) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Vraylar (Cariprazine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $48.5295/unit (~$1455.88/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Vraylar (Cariprazine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vraylar (Cariprazine) RxNorm Concept ID | RXN-B61874130 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $48.5295 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vraylar (Cariprazine) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Vraylar (Cariprazine) integrating DailyMed SPL (2026-07-01), CMS NADAC ($48.5295/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vraylar (Cariprazine) community threads and patient logs by age, biological sex, dosage, and treatment duration.